MetLife Investment Management LLC Has $727,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
by Sarita Garza · The Markets Daily
MetLife Investment Management LLC lifted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 9.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,755 shares of the company’s stock after acquiring an additional 3,126 shares during the quarter. MetLife Investment Management LLC owned approximately 0.05% of Syndax Pharmaceuticals worth $727,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. ExodusPoint Capital Management LP acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at about $1,307,000. Exchange Traded Concepts LLC increased its position in shares of Syndax Pharmaceuticals by 740.7% in the second quarter. Exchange Traded Concepts LLC now owns 7,213 shares of the company’s stock valued at $151,000 after acquiring an additional 6,355 shares during the last quarter. Panagora Asset Management Inc. increased its position in shares of Syndax Pharmaceuticals by 1.8% in the first quarter. Panagora Asset Management Inc. now owns 182,381 shares of the company’s stock valued at $3,852,000 after acquiring an additional 3,296 shares during the last quarter. PAX Financial Group LLC acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at about $501,000. Finally, Jennison Associates LLC increased its position in shares of Syndax Pharmaceuticals by 4.4% in the second quarter. Jennison Associates LLC now owns 2,521,916 shares of the company’s stock valued at $52,784,000 after acquiring an additional 105,462 shares during the last quarter.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Syndax Pharmaceuticals in a report on Wednesday, October 11th. They set a “buy” rating and a $30.00 price target for the company. Bank of America assumed coverage on Syndax Pharmaceuticals in a report on Wednesday, October 25th. They set a “buy” rating and a $29.00 price target for the company. Scotiabank reduced their price target on Syndax Pharmaceuticals from $39.00 to $36.00 in a report on Tuesday, October 3rd. StockNews.com assumed coverage on Syndax Pharmaceuticals in a report on Thursday, October 5th. They set a “sell” rating for the company. Finally, Robert W. Baird reduced their price target on Syndax Pharmaceuticals from $32.00 to $28.00 in a report on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $35.09.
Get Our Latest Stock Report on Syndax Pharmaceuticals
Syndax Pharmaceuticals Price Performance
Shares of SNDX opened at $16.77 on Wednesday. Syndax Pharmaceuticals, Inc. has a one year low of $11.22 and a one year high of $29.86. The company has a market cap of $1.17 billion, a P/E ratio of -6.50 and a beta of 1.07. The firm has a 50 day simple moving average of $13.94 and a two-hundred day simple moving average of $17.71.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.07. On average, analysts expect that Syndax Pharmaceuticals, Inc. will post -2.97 earnings per share for the current fiscal year.
Syndax Pharmaceuticals Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).
Featured Stories
- Five stocks we like better than Syndax Pharmaceuticals
- How to Calculate Stock Profit
- What is dividend harvesting?
- When to Sell a Stock for Profit or Loss
- Investing in quantum computing: A guide
- How to Buy Cheap Stocks Step by Step
- Marvell Technology at a critical pivot: 30% upside is possible
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report).